JP2015517484A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517484A5
JP2015517484A5 JP2015510875A JP2015510875A JP2015517484A5 JP 2015517484 A5 JP2015517484 A5 JP 2015517484A5 JP 2015510875 A JP2015510875 A JP 2015510875A JP 2015510875 A JP2015510875 A JP 2015510875A JP 2015517484 A5 JP2015517484 A5 JP 2015517484A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
sequence
peptide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015510875A
Other languages
English (en)
Japanese (ja)
Other versions
JP5982562B2 (ja
JP2015517484A (ja
Filing date
Publication date
Priority claimed from GB201208293A external-priority patent/GB201208293D0/en
Application filed filed Critical
Publication of JP2015517484A publication Critical patent/JP2015517484A/ja
Publication of JP2015517484A5 publication Critical patent/JP2015517484A5/ja
Application granted granted Critical
Publication of JP5982562B2 publication Critical patent/JP5982562B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015510875A 2012-05-11 2013-05-09 ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途 Expired - Fee Related JP5982562B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1208293.9 2012-05-11
GB201208293A GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide
PCT/GB2013/051201 WO2013167897A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Publications (3)

Publication Number Publication Date
JP2015517484A JP2015517484A (ja) 2015-06-22
JP2015517484A5 true JP2015517484A5 (enExample) 2016-06-30
JP5982562B2 JP5982562B2 (ja) 2016-08-31

Family

ID=46396890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510875A Expired - Fee Related JP5982562B2 (ja) 2012-05-11 2013-05-09 ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途

Country Status (17)

Country Link
US (1) US9657061B2 (enExample)
EP (1) EP2847209B8 (enExample)
JP (1) JP5982562B2 (enExample)
KR (1) KR20150014955A (enExample)
CN (1) CN104428311B (enExample)
AU (1) AU2013257784A1 (enExample)
BR (1) BR112014028130A2 (enExample)
CA (1) CA2873120A1 (enExample)
EA (1) EA201492068A1 (enExample)
GB (2) GB201208293D0 (enExample)
HK (1) HK1201850A1 (enExample)
IL (1) IL235388A (enExample)
IN (1) IN2014DN09367A (enExample)
MX (1) MX2014013394A (enExample)
SG (1) SG11201407446TA (enExample)
WO (1) WO2013167897A1 (enExample)
ZA (1) ZA201408290B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
PL3545965T3 (pl) 2014-12-23 2021-12-27 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka
FI3273986T3 (fi) 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
EP4021920A4 (en) * 2019-08-26 2023-08-16 Auro Peptides LTD IMPROVED PROCESS FOR PRODUCTION OF ETELCALCETIDE HYDROCHLORIDE
BR112022010101A2 (pt) * 2019-12-31 2022-09-06 Pfizer R&D Uk Ltd Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469078A1 (en) * 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
AU2007207618B2 (en) 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EA023303B1 (ru) * 2007-08-15 2016-05-31 Сиркейшиа Лимитед Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
JP5869553B2 (ja) * 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤

Similar Documents

Publication Publication Date Title
NZ759512A (en) Delayed release compositions of linaclotide
PE20241305A1 (es) Analogos de amilina
PH12018550201A1 (en) Hepatitis b antiviral agents
JP2015078230A5 (enExample)
PH12018502465A1 (en) Mic-1 compounds and use thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
JP2020513418A5 (enExample)
JP2015513318A5 (enExample)
TN2013000257A1 (en) Immunosuppressant formulations
MX2021006969A (es) Ligante peptidico.
EP4653537A3 (en) Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
TW201613557A (en) Stable aqueous recombinant protein formulations
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
JP2018529626A5 (enExample)
WO2015024022A3 (en) Designed peptides for tight junction barrier modulation
WO2012162637A3 (en) Vaccine adjuvants from self-assembling peptides
JP2013542196A5 (enExample)
JP2017007966A5 (enExample)
JP2016160183A5 (ja) 筋萎縮抑制剤及び筋萎縮抑制用飲食品
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
PH12013500558A1 (en) Solid state forms of a potent hcv inhibitor